According to Future Market Insights (FMI) in a recent market analysis, the Global HPV testing and Pap Test Market Size was valued at US$ 2.2 billion in 2021 and is predicted to reach US$ 15 billion by 2032. According to the report’s findings, Pap Testing will continue to be crucial for the industry, as it will create the majority of revenue, with a CAGR of 17.5%. Official plans and regulations, such as the WHO global cervical cancer elimination strategy, are projected to increase demand for testing. New technology, government programmes, and public awareness campaigns will all assist to increase demand in low-resource countries.
Unlock growth potential with industry expertise. Download your market sample report now: https://www.futuremarketinsights.com/reports/sample/rep-gb-15811
Cervical Cancer Screening to Continue being the key application for HPV and Pap Test Revenue
Vaginal cancer cannot be discovered just with Pap or HPV tests. However, they can identify cervical cancer, HPV, and pre-cancerous diseases. This is useful because the existence of them can be a risk factor for cervical cancer.
The US to Command the Larger Proportion of HPV testing and Pap test consumption in the Analysis Period
The United States contributed the most to the increase in demand for HPV and Pap tests. The American Cancer Society suggests monitoring women over the age of 25 at prescribed intervals. There are additional programmes that offer free or low-cost testing to women, such as the CDC’s NBCCEDP.
HPV testing and Pap Test Market: Competition Insights
HPV Testing and Pap Test providers are focused on increasing the efficiency, accuracy and affordability of their tests and harnessing new technology. The key companies operating include Abbott Laboratories, Qiagen N.V., Becton, Dickinson and Company, Quest Diagnostics, Inc., Hologic, Inc., F. Hoffmann-La Roche, Femasys, Inc., Arbor Vita Corporation, NURX, Inc., Seegene, Inc., Thermo Fisher Scientific. Inc., bioMérieux SA
Get HPV testing and Pap Test Market Report At a Discounted Price: https://www.futuremarketinsights.com/request-discount/rep-gb-15811
Some of the recent developments in HPV Testing and Pap Test are as follows:
- Hoffmann-La Roche AG, a Swiss-based healthcare pharmaceutical and diagnostics firm, announced the launch of a self-sampling option in June 2022, through which patients can collect samples privately at a healthcare institution under instructions and have them analysed. The goal of allowing self-collection was to offer an alternative to the traditional intrusive clinician-based collection technique.
- Alercell, Inc, a molecular diagnostics firm and diagnostics provider, announced the “Meltpro HPV genotype test” in May 2022. It is based on DNA sequencing research. The use of a PCR machine eliminates the risk of human interpretation and results in less than three hours.
- In the summer of 2022, Karkinos Healthcare developed CerviRaksha, a clinically validated HPV test that has been pre-qualified and approved by the World Health Organisation (WHO) and the United States Food and Drug Administration (FDA). It has also been granted the CE mark and bears it. The samples are gathered at home, and the findings are sent by email. Individual HPV-16 and HPV-18 genotypes are differentiated, and false positives are filtered.
- In May 2022, The London School of Hygiene and Tropical Medicine and the University of Manchester, and the University of Hull will collaborate to test for cervical cancer in women of the 65-and-older age group, who are often overlooked despite accounting for over 50% of cervical cancer incidents in the UK. This test will also only require a urine sample, which might encourage women who were opting out of the test to take part.
Customize Your Report Now: https://www.futuremarketinsights.com/customization-available/rep-gb-15811
More Insights Available
Future Market Insights, in its new offering, presents an unbiased analysis of the HPV Testing and Pap Test Market, presenting historical market data (2017 to 2021) and forecast statistics for the period of 2022 to 2032.
The study reveals essential insights on the basis of by Test Type (HPV Testing, Pap Test), By Application (Vaginal Cancer Screening, Cervical Cancer Screening), By Product Type (Instruments, Consumables, Services), by Technology (PCR, Immunodiagnostics, Other Technologies), across five regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs